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A novel CBCT-based method for derivation
of CTV-PTV margins for prostate and pelvic
lymph nodes treated with stereotactic
ablative radiotherapy
Ciara A. Lyons1,2, Raymond B. King1,3*, Sarah O.S. Osman1,3, Stephen J. McMahon1, Joe M. O’Sullivan1,2,
Alan R. Hounsell1,3, Suneil Jain1,2 and Conor K. McGarry1,3
Abstract
Background: Traditional CTV-PTV margin recipes are not generally applicable in the situation of stereotactic
ablative radiotherapy (SABR) treatments of multiple target volumes with a single isocentre. In this work, we present
a novel geometric method of margin derivation based on CBCT-derived anatomical data.
Methods: Twenty patients with high-risk localized prostate cancer were selected for retrospective review. Individual
volumes of interest (prostate, prostate and seminal vesicles and pelvic lymph nodes) were delineated on five representative
CBCTs and registered to the planning CT using two registration protocols: bone match or prostate-based soft tissue match.
Margins were incrementally expanded around composite CTV structures until 95% overlap was achieved.
Results: CTV-PTV margins of 5.2, 6.5 and 7.6 mm were required for prostate, prostate and seminal vesicles and pelvic
lymph nodes respectively using a prostate matching protocol. For the prostate and seminal vesicle structures, margins
calculated using our method displayed good agreement with a conventional margin recipe (within ±1.0 mm).
Conclusions: We have presented an alternative method of CTV-PTV margin derivation that is applicable to SABR
treatments with more than one isocentric target. These results have informed an institutional trial of prostate and pelvic
nodal SABR in men with high-risk localized prostate cancer.
Keywords: SABR, Stereotactic radiotherapy, Margin derivation, Prostate cancer, Elective nodal irradiation, Multiple isocentric
targets
Introduction
Stereotactic ablative radiotherapy (SABR) is increasingly
used for the treatment of prostate cancer (PC), which is
sensitive to larger fraction size due to a low α/β ratio
[1–4]. Improved accuracy in treatment delivery, particu-
larly since the widespread adoption of cone-beam CT
(CBCT), has enabled reductions in CTV-PTV margins,
facilitating dose escalation while also reducing the risk of
toxicity [5–7]. Geometric accuracy is particularly important
in the setting of SABR. Due to the high fractionation dose,
steep dose gradients and smaller margins, a geographic
miss in a single fraction could lead to considerable target
under-dosing and an increased risk of toxicity [1, 8, 9].
To date, the majority of prostate SABR evidence has
been for low- to medium-risk groups, where generally
the prostate alone is treated [2–4]. There is a relative
paucity of data regarding the use of SABR in men with
high-risk prostate cancer, who potentially have the most
to gain from dose escalation [10]. For this patient cohort
elective pelvic nodal irradiation (ENI) is delivered in
many centres, for patients treated with conventionally
fractionated radiotherapy [11]. Results from a phase I/II
5-fraction SABR trial, where 25Gy was delivered to
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pelvic node CTVs simultaneously with a 40Gy prostate
CTV prescription dose, indicated that the treatment was
well tolerated in the acute setting with further follow-up
data expected in the future [12].
Our centre is also currently recruiting to a high-risk
prostate SABR trial with an ENI arm, where 50% of
patients are prescribed 25 Gy to a pelvic node PTV,
delivered simultaneously with 36.25Gy to the prostate
PTV over 5 fractions [13]. However, the use of conven-
tional margin recipes in the situation of SABR for elect-
ive pelvic nodal irradiation is potentially suboptimal, as
they rely on a number of assumptions that are not met
in this scenario. A fundamental assumption that is un-
realistic in this case is that the target’s geometry is typic-
ally modelled as a rigid sphere. Not only is the shape of
the pelvic nodal CTV structure overtly complex, but it is
also subject to considerable daily variation that is
dependent on bladder filling as well as other parameters
[14–17].
Conventional CTV-PTV margin calculations are also
not easily applicable to irradiation of multiple targets via
a single treatment isocentre. For example, the prostate
and lymph node CTV structures are known to move in-
dependently relative to each other, with displacements of
up to 6 mm reported [14]. Additional consideration
must therefore be given when employing an image guid-
ance regime that only matches to the primary target site
(e.g. the prostate).
This paper describes a composite volume approach
that allows derivation of margins for two or more separ-
ate CTVs treated using a single isocentre; in this case,
the prostate (PO), prostate and seminal vesicles (PSV)
and pelvic lymph nodes (LN). This composite volume
method was used to calculate individual margins for
each structure, with the PO and PSV margins subse-
quently compared to PO/PSV margins derived using a
commonly employed conventional statistical method
[18].
Methods
Patients, treatment planning and delivery
Twenty patients, previously treated with conventionally
fractionated radical radiotherapy to the prostate and pel-
vis, were selected for this retrospective review. Each pa-
tient had planning CT (pCT) images acquired using a
helical CT-simulator (512 × 512 field of view, 1 mm
axial pixel resolution, 2.5 mm slice width). All patients
were instructed to empty their bladder and to drink
500 mL of water and had a micro-enema (Micralax®) ad-
ministered prior to their pCT and each treatment ses-
sion. The pCT images were imported into Eclipse™
v13.5.35 (Varian Medical Systems, Palo Alto, CA) for
contouring target and organ at risk (OAR) volumes.
Target volumes of interest (PO, PSV and LN) were indi-
vidually delineated following a previously described pel-
vis IMRT protocol [19].
All treatments were delivered using a Varian True-
Beam™ linac (Varian Medical Systems) with kV-based
CBCT on-board imaging. Patient set-up and CBCT veri-
fication imaging were carried out as per our institutional
protocol: images were acquired following set-up for the
first three fractions of treatment and on a weekly basis
subsequent to this. For treatment delivery, online regis-
tration of CBCT images to the pCT was performed
using the patient’s bony anatomy as a surrogate for the
PTV; however, these registrations were not used in this
investigation.
Image registration
Additional offline registrations of the CBCT images to
the pCT were performed independently to the online
registration by a single clinical oncologist (CL), using the
registration workspace within Eclipse™. Only transla-
tional shifts were considered in all cases. Two image
matching protocols were studied – bone (bony pelvis)
and soft tissue (ST, prostate-based), resulting in two sep-
arate datasets for analysis. Every match pair was per-
formed in the same order: in all cases, an automated
pelvic bone match was carried out first, this was
followed by a separate automated ST match using the
prostate as the common reference, with the resulting
registration manually adjusted where required.
Contouring
Five CBCT image sets were selected for each patient (to
reflect commonly used SABR fractionation schedules)
[12, 20]. To generate an appropriate representation of
the variation in individual patient anatomy throughout
their entire treatment, the first and last CBCT image
sets were selected for each patient, with the remaining 3
CBCT image sets evenly sampled across the patient’s
treatment schedule. CBCT image sets with optimum
image quality were selected for analysis to ensure accur-
acy in the soft-tissue structures delineated and image
sets of insufficient image quality were excluded from the
study. Following registration of the CBCT images to the
pCT, structures of interest were contoured manually in
Eclipse™ by a single clinical oncologist (CL) and peer-
reviewed by a second clinical oncologist (SJ).
Composite volume generation and overlap analysis
Volumes contoured on each CBCT were transferred to a
single pCT structure set. Two datasets per patient were
created, which accounted for translational shifts deter-
mined from each registration method (i.e., bone and ST
matches). Fig. 1a shows an example of LN axial contours
from five different CBCTs (cyan) overlaid on the
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corresponding pCT axial slice; in this example, a ST
match to the prostate was used to register each of the
CBCT images to the pCT.
The image-registration and contouring tools available
within Eclipse™ were used to combine the CBCT con-
tours and to compare the resulting composite structure
(blue) to the CTV structures originally delineated on
each patient’s pCT (red). CBCT contours that were
transferred using the same registration method (bone or
ST) were combined to create two separate composite
structures. A 3D rendering comparing the original pCT
LN CTV structure (red) to the ST-matched composite
structure (blue) is also illustrated in Fig. 1b, with the
pCT PSV structure (pink) included for reference. The
volume of each composite structure was recorded and
used for subsequent analysis.
A uniform margin was incrementally increased around
the pCT CTV structure (0 to 12 mm; 1 mm increments)
to generate a series of PTVs for these structures. For
each margin increment, the volume of the overlapping
region between the generated PTV and each of the com-
posite structures (bone or ST match) was determined.
Fig. 1c shows an example of this analysis on the same
axial slice shown in Fig. 1a. In this example, a 3 mm
margin has been uniformly extended around the CTV to
generate the PTV. Overlapping regions between the
PTV and the composite volume are indicated by the
green-shaded areas, while the purple-shaded areas indi-
cate non-overlapping regions. The overlapping volume
was expressed as a percentage of the composite struc-
ture for each PTV margin increment. Additional illustra-
tive examples of this technique are provided in
Additional file 1.
Margin calculation
To correlate with other margin derivation methods [18],
a percentage overlap of 95% was selected as the desired
threshold criterion. The margins required to achieve
95% overlap for each individual patient and registration
option were determined through linear interpolation of
the relevant increments.
A population margin was then determined for the 20
patients sampled. Again, as with other techniques, the
population margin was defined as the margin required
to achieve the desired 95% overlap in 90% of the patient
population. For a normal distribution, this can simply be
determined from the mean ( x ) and standard deviation
(s) of the sampled group, using the formula:
Margin ¼ x þ 1:28s ð1Þ
PO and PSV margins were then calculated using a
commonly used conventional statistical method [18] and
compared to those calculated using our composite vol-
ume technique. Systematic (Σ) and random (σ) errors,
obtained from analysis of a recent audit of our institu-
tional set-up protocol, were employed to determine mar-
gins for the two set-up protocols, using the following
margin recipe [18]:
Margin ¼ 2:5Σþ 0:7σ ð2Þ
It is worth noting that this conventional recipe assumes
that treatments consist of a very large number of treat-
ment sessions, each delivering a very small dose fraction,
Fig. 1 a Composite volume generation for soft tissue-registered LN
CTV contours. b 3D rendering of the original pCT LN CTV and the
soft tissue composite LN structure. c Overlap analysis for a uniform
3 mm margin
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effectively assuming an infinite number of treatment ses-
sions to simplify the mathematical method [18, 21]. These
assumptions are clearly not met with SABR treatments
and alternative methods have been proposed to address
this limitation [21, 22]. However, margin calculations
performed using an adapted version of this conventional
recipe (VH1 described in [22]) with our derived systematic
and random errors agreed well (≤0.3 mm deviation) with
the conventional recipe and therefore only the conven-
tional margins are compared with our composite volume
method.
Additional data are supplied in the Additional file 2.
Statistical methods
MATLAB v8.2.0 (MathWorks, Natick, MA) was used to
perform a two-sided Wilcoxon signed-rank test to assess
the significance in differences between the percentage
overlap distributions obtained for each margin incre-
ment for the two image-registration matching scenarios
(where p < 0.05 was considered statistically significant).
For both image-matching protocols, a Shapiro-Wilk
normality test was performed using SPSS v22.0.0 (IBM,
Armonk, NY), to determine whether the individual mar-
gins required to achieve 95% overlap for the 20 patients
were normally distributed.
Results
A total of 120 CT images were individually contoured
(20 pCTs and 100 CBCTs). For each target structure
(PO, PSV and LN), a minimum of 9 different CTV-PTV
margin sizes were analyzed to determine the percentage
overlap of the PTV structure with the CBCT composite
structures produced for either a bone or ST match.
The results of the percentage overlap analysis for the
three target structures for all 20 patients analyzed are
displayed as box-whisker plots in Fig. 2. Differences be-
tween the median values of the population overlap dis-
tributions for the two registration options (bone or ST)
were statistically significant (p < 0.05) for all structures
and margin sizes investigated.
Table 1 reports the mean and standard deviation of
the 95% overlap margin for each of the structures and
registration options, as well as additional results ob-
tained from the composite volume analysis. The ratio of
the composite to pCT volume was 1.40 and 1.33, 1.57
and 1.44 and 1.22 and 1.33 respectively for bone and ST
matches for the PO, PSV and LN structures. As an ex-
ample, employing a CTV-PTV margin of 5 mm, and
using a prostate-based ST match, the average percentage
overlap of the composite CBCT volume with the pCT
volume was 98.0%, 96.6% and 93.6% for the PO, PSV
and LN structures respectively.
Table 2 reports the population CTV-PTV margins for
the composite volume and conventional statistical
techniques. The composite volume analysis indicated
PO population margins of 8.3 and 5.2 mm (s = 2.83 and
1.87 mm) for bone and ST matches respectively. For the
PSV structures, calculated population margins were 9.9
and 6.5 mm for the bone and ST matches.
The bone-matching protocol required smaller margins
around the LN structures, indicating that a margin of
5.9 mm was required to achieve 95% overlap in 90% of
the patients. A margin of 7.6 mm was calculated for the
LN CTV structure when a prostate-based ST match was
performed. Margins calculated using the composite vol-
ume method for the PO and PSV structures showed
good agreement with the results of the conventional
Fig. 2 Box-whisker plots of the percentage overlap distributions for
the (a) prostate (PO) structure, (b) prostate and seminal vesicles
(PSV) structure, and (c) pelvic lymph node (LN) CTV. Differences
between the two image-matching protocols were significant for all
target structures and margin sizes (p < 0.05). The whiskers indicate
the last percentage overlap value within 1.5× the interquartile range
of its nearest quartile. Individual data points (+/○) represent patient
outliers with percentage overlap values outside of this range
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margin recipe. The margin calculated for the PSV struc-
ture using a bone-matching protocol was within 0.5 mm
of that derived using the statistical method (9.9 and
9.4 mm for the composite volume and conventional
techniques respectively).
Additional data for individual patients and margin
increments are supplied in the Additional file 3.
Discussion
A new alternative method to determine planning margins
in scenarios where complex multiple-target volumes are
treated with a single isocentre has been described. The
technique employs a similar methodology to that used by
Mak et al. to evaluate seminal vesicle inter-fraction mo-
tion and its relationship to rectal and bladder filling [23].
The current methodology allows derivation of set-up mar-
gins but could potentially be adapted to include delinea-
tion and intrafraction motion errors through the use of
additional contours drawn by independent observers and
including contours from post-treatment CBCT images
[24]. Margins included soft tissue geometrical information
obtained from repeat CBCT images as opposed to transla-
tional registration errors used traditional margin recipes.
Using a prostate-based ST match, this composite vol-
ume analysis yielded margins of 5.2, 6.5 and 7.6 mm for
PO, PSV and LN volumes respectively. The PO and PSV
margins showed good agreement with PO/PSV margins
derived using a conventional statistical margin recipe
that included delineation uncertainty and intrafraction
motion errors [18]. These margins were also very similar
to the lower limit values determined by Oehler et al.,
who reported CTV-PTV margins of between 5 and
8 mm for PO and 6-11 mm for PSV structures, again
using the conventional method with delineation uncer-
tainty and intrafraction motion errors included [24].
As expected, this new analysis indicated that matching
to the prostate requires relatively smaller PO and PSV
margins and a larger margin around the LN CTV, thus
facilitating margin reduction around the high-dose
targets and minimising the volume of normal tissue
receiving higher doses of radiation. Many institutions
commonly include the PSV and LN when treating men
with high-risk localized PC [25, 26]. It is therefore
important to accurately quantify the CTV-PTV margins
required for each target structure when matching to the
prostate structure as small changes have the potential to
cause much larger shifts in the LN CTV [15, 27].
A number of studies have reviewed LN margins in the
context of conventionally fractionated prostate and pel-
vic radiotherapy, each adopting a different approach and
consequently reporting a range of nodal CTV-PTV mar-
gins. For example, Ferjani et al. mapped original plan-
ning structures to selected CBCTs using bone and
prostate matches for six patients [16]. They then applied
the original IMRT plan (recalculated without heterogen-
eity correction) to estimate the dose based on both
matches for a given CBCT. They concluded that CTV-
PTV margins of 8 mm (6 mm posteriorly) to the pros-
tate and 5 mm to the LN were sufficient for concurrent
treatment with CBCT prostate-based matching.
By evaluating relatively more image sets for fewer
patients than our study, Ferjani et al.’s results provide a
Table 1 Volume and individual margin characteristics for the pCT target structures and the composite structures generated from
contours on the CBCT images
Structure PO PSV LN
Match type Bone ST Bone ST Bone ST
pCT CTV volume (cm3) Average 25.9 36.1 360.2
Std. Dev. 10.5 14.1 55.2
Composite volume
pCT volume Average 1.40 1.33 1.57 1.44 1.22 1.33
Std. Dev. 0.23 0.24 0.36 0.26 0.16 0.22
% overlap with 5 mm margin Average 93.4 98.0 90.5 96.6 95.9 93.6
Std. Dev. 6.64 2.51 8.96 3.72 1.34 3.15
95% overlap margin (mm) Average (x) 4.71 2.83 5.71 3.79 3.93 5.55
Std. Dev. (s) 2.83 1.87 3.29 2.13 1.50 1.59
Table 2 Population margins calculated using a conventional
margin recipe [18] and the composite volume technique for
each image-matching scenario
Match type Technique Structure Margin (mm)
Bone Margin Recipe PO/PSV 9.4
Composite volume PO 8.3
PSV 9.9
LN 5.9
Soft Tissue (prostate) Margin Recipe PO/PSV 6.7
Composite volume PO 5.2
PSV 6.5
LN 7.6
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better indication of intra-patient variability. However, by
including a larger sample size (n = 20) and manually de-
lineated individualized CTVs for each CBCT, our study
provides a strong indication of inter-patient variability
and a more accurate representation of the true treat-
ment anatomy. Additionally, given the uncertainties in-
herent in CBCT-based dose modeling [28], we elected to
pursue a purely anatomy-based approach.
The 5 mm LN margin recommended by Ferjani et al.
is substantially smaller than the ≥13 mm “vascular
space” margin recommended by Wang et al., which was
also based on a prostate-matching regime [14]. Wang et
al.’s margin was derived by mapping three separate
IMRT plans (with varying CTV-PTV margin) onto serial
CBCTs for eight patients. The dose computed on each
CBCT was subsequently mapped back to the original
pCT and summed to generate DVHs for each structure
of interest which were analyzed to determine the
optimum margin.
Hinton et al. employed another technique which used
measured couch shifts to derive nodal CTV-PTV margins
of 9 mm in the anterior-posterior direction and 7 mm lat-
erally [15]. These margins are similar (<1.4 mm difference)
to those calculated in our study which considered an iso-
tropic margin expansion in all three Cartesian planes as
analysis of each patient’s composite volume indicated
comparable structure motion in all three directions.
With regard to SABR, in a single study, Kishan et al.
used fiducial-based CBCT matching to evaluate 12 pa-
tients [17]. Selected CBCTs were registered to the pCT,
allowing transfer of dose distributions and the original
pCT contours. They found that standard LN margins of
4-5 mm were acceptable, under the conditions that the
superior displacement of the prostate was kept to
≤5 mm and the relative change in bladder height was
<18%. This margin is considerably smaller than the
7.6 mm calculated from our analysis, which avoided
CBCT dose calculation uncertainty and used delineated
structures based on actual CBCT anatomy.
The authors acknowledge that there are some limitations
to the current study. Firstly, post-treatment CBCT, pitch /
roll and rotational corrections and real-time tracking of the
prostate were not incorporated, reflecting current clinical
practice in our and many other institutions. However, avail-
able data indicate that these are largely accounted for by
conventional margin expansion in SABR [29–31] and future
extensions to the technique are planned to confirm this.
Secondly, the ST resolution with CBCT is poorer than with
conventional CT, particularly with regard to delineation of
the prostate-rectum interface [32–34]. This issue, in
conjunction with potential errors with image-matching, is
an inherent feature of this type of study [35, 36]. In this
investigation, CBCTs of insufficient image quality were not
included in the analysis and a single experienced uro-
oncologist (CL) contoured and matched all CTs following a
well-defined protocol [19], and a second clinical oncologist
(SJ) peer-reviewed the resulting structures and registrations.
While contouring of serial CBCTs is currently a time-
intensive process that is not routinely implementable into
clinical workflow, rapid advances in auto-contouring algo-
rithms may facilitate wider adoption of this method. Finally,
due to the inherent difficulties in performing accurate dose
calculations using CBCT [37], this study only evaluated geo-
graphic changes and did not include a dosimetric analysis.
Particular strengths of this study include the sample size
and number of CBCTs evaluated, the use of individually
contoured LN CTVs for pCTs and CBCTs, and the inde-
pendence of the composite volume CTV-PTV margin
derivation method from the assumptions of conventional
margin recipes. In many previous studies, couch shifts
[38], representative slices [15] or the original nodal CTV
alone [39] were chosen to represent serial nodal CBCT
CTVs. In addition, the superior-inferior CTV-PTV margin
was not accounted for in some cases [15]. In this study,
the entirety of each volume was considered in all three
planes. Individual protocol-based CTVs were generated
for all 100 CBCTs in a more accurate reflection of the true
anatomical situation during treatment. This is particularly
important in the case of the LN CTV, due to the greater
impact of variability of the size and position of the OARs.
The results of this analysis will be utilized in an institu-
tional trial of prostate and pelvic nodal SABR in men with
high-risk localized PC [13]. However, this method could
also be applied to other sites where multiple target vol-
umes are treated with a single isocentre.
Conclusions
Current methods of CTV-PTV margin calculation for
conventional radiotherapy may not be sufficient for the
derivation of margins in the setting of SABR and/or
multiple isocentric CTVs. We have presented a novel
method of CTV-PTV margin derivation that is applic-
able to the single isocentre treatment of more than one
target volume and/or SABR. When applied to prostate
and seminal vesicle target structures, which are a good
facsimile for the target geometries assumed in conven-
tional margin recipes, this method yielded comparable
results to conventional methods. Margins calculated
from this analysis have been used to inform an institu-
tional prostate and pelvic nodal SABR trial.
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